Finch Therapeutics Group, Inc

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

In operation since 1981, Genzyme Corporation is one of the leading biotechnology companies in the world. The company employs a staff of more than 12,000 people and manages over 85 locations in nearly 40 countries. It focuses on the areas of hematologic oncology, biosurgery, transplant, genetic diseases, and cardiometabolic and renal. Genzyme Corporation offers Fabrazyme, which is a solution for intravenous infusion. The company also provides Fabrazyme, Renagel, Renvela and Hectorol. It offers solutions for the medical and patient communities. In addition, Genzyme Corporation offers Synvisc, which is a viscosupplementation treatment for relieving knee pain associated with osteoarthritis. The company provides Sepra, which is a line of hyaluronic acid-based products.

Momenta Pharmaceuticals is a biotechnology company that specializes in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. The company also utilizes its ability to sequence the molecular structure of sugars to create technology-enabled generic versions of complex sugar-based products. Its advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox, an often-prescribed low molecular weight heparin. The company s technology provides a better understanding of the roles that sugars play in cellular function, disease and drug action. Momenta Pharmaceuticals is headquartered in Cambridge, Mass.